Nahum Victoria, Tulapurkar Mohan, Lévesque Sébastien A, Sévigny Jean, Reiser Georg, Fischer Bilha
Department of Chemistry, Gonda-Goldschmied Medical Research Center, Bar-Ilan University, Ramat-Gan 52900, Israel.
J Med Chem. 2006 Mar 23;49(6):1980-90. doi: 10.1021/jm050955y.
Dinucleoside polyphosphates, NpnN', exert their physiological effects via P2 receptors. They are attractive drug targets as they offer better stability and specificity compared to nucleotides, the most common P2-receptor ligands. To further improve the properties of NpnN', which are still pharmacologically unsatisfactory, we developed novel boranophosphate isosteres of dinucleoside polyphosphates, denoted as Npn(B)N. These analogues were obtained in a facile and efficient synthesis as the exclusive products in a concerted reaction of two nucleoside phosphorimidazolides and inorganic boranophosphate. This unusual reaction is due to the preorganization of three reactant molecules by the Mg2+ ion. We found that Ap3/5(beta/gamma-B)A analogues were potent P2Y1-R agonists. Ap5(gamma-B)A was equipotent to 2-MeS-ADP (EC50 6.3x10(-8) M), thus making it one of the most potent P2Y1-R agonists currently known. Moreover, Ap5(gamma-B)A did not activate P2Y2-R. In contrast, Up3/5(beta/gamma-B)U analogues were extremely poor agonists of both P2Y1-R and P2Y2-R. Npn(B)N analogues exhibited remarkable chemical stability under physiological conditions. Under conditions mimicking gastric juice, Np3(beta-B)N analogues exhibited a half-life (t1/2) of 1.3 h, whereas Np5(gamma-B)N degraded at a much faster rate (t1/2 18 min). The hydrolysis of Ap3(beta-B)A by human nucleotide pyrophosphatase phosphodiesterases (NPP1 and NPP3) was slowed by 40% and 59%, respectively, as compared to Ap3A. However, this effect of the boranophosphate was position-dependent, as Np5(gamma-B)N was degraded at a rate comparable to that of Np5N. In summary, Ap5(gamma-B)A appears to be a highly potent and selective P2Y1-R agonist, as compared to the parent compound. This promising scaffold will be applied in the design of future metabolically stable analogues.
二核苷多磷酸酯(NpnN')通过P2受体发挥其生理作用。与最常见的P2受体配体核苷酸相比,它们具有更好的稳定性和特异性,是有吸引力的药物靶点。为了进一步改善NpnN'的性质(其在药理学上仍不尽人意),我们开发了新型的二核苷多磷酸酯硼代磷酸酯类似物,记为Npn(B)N。这些类似物通过两个核苷磷酰咪唑和无机硼代磷酸酯的协同反应以简便高效的合成方式作为唯一产物获得。这种不寻常的反应是由于Mg2+离子对三种反应物分子的预组织作用。我们发现Ap3/5(β/γ-B)A类似物是强效的P2Y1-R激动剂。Ap5(γ-B)A与2-MeS-ADP等效(EC50为6.3×10(-8) M),因此使其成为目前已知的最有效的P2Y1-R激动剂之一。此外,Ap5(γ-B)A不激活P2Y2-R。相比之下,Up3/5(β/γ-B)U类似物是P2Y1-R和P2Y2-R的极弱激动剂。Npn(B)N类似物在生理条件下表现出显著的化学稳定性。在模拟胃液的条件下,Np3(β-B)N类似物的半衰期(t1/2)为1.3小时,而Np5(γ-B)N的降解速度要快得多(t1/2为18分钟)。与Ap3A相比,人核苷酸焦磷酸酶磷酸二酯酶(NPP1和NPP3)对Ap3(β-B)A的水解分别减慢了40%和59%。然而,硼代磷酸酯的这种作用是位置依赖性的,因为Np5(γ-B)N的降解速度与Np5N相当。总之,与母体化合物相比,Ap5(γ-B)A似乎是一种高效且选择性的P2Y1-R激动剂。这个有前景的支架将应用于未来代谢稳定类似物的设计。